(6aR,9R)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: (6aR,9R)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• 化学式: C₃₃H₄₁BrN₄O₅
• 分子量: 653.6
• InChiKey: DNBXLOFOFOEMEP-CJXGXNFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  43
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• BROMOCRIPTINE FORMULATIONS
  申请人：VeroScience LLC

  公开号：US20140187560A1

  公开（公告）日：2014-07-03

  The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes.
• COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS
  申请人：Boehringer Ingelheim Vetmedica GmbH

  公开号：US20170239281A1

  公开（公告）日：2017-08-24

  The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadreeocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis. polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite.
• US9192576B2
  申请人：——

  公开号：US9192576B2

  公开（公告）日：2015-11-24